Dr. Susan Galbraith

One of the other things that we're obviously looking at is the potential for a biomarker for Detroway to improve the patient selection.

And I think that's another important opportunity for differentiation as well.

So are you looking forward to this?

I am looking forward to the data.

I mean, the Artemido 1 data, as it continues to mature, patients are staying on treatment.

There's really good tolerability and those durability response data and the progression-free survival data, more than 12 months, medium progression-free survival in the patients that have more than 50% of,

is that there is an extension of the range of patients that are likely to to respond and that's across multiple data sets that we've got as well and then the the tolerability profile and the durability of response is also very encouraging so this is one of the reasons why we've had confidence in the program to advance into multiple in your comment there i hear whether

Thanks, Sam.

It's always good to talk to you.

Take care.

Bye-bye.